Insider Trading Review: Insys Therapeutics, Inc. $INSY

c7c716a4f9a8924c760326247a23fcc5

Insys Therapeutics, Inc. (INSY) insider have most recently took part in a trading activity. On Jun 14, 2017 Motahari Saeed, President & CEO bought 5,400 shares having total worth of $59,940 at the price of $11.1 per share, following the transaction a total of 9,900 shares owned by Motahari Saeed. Before this latest buy, Motahari Saeed purchased INSY at 1 other times during the past twelve months, for a total investment of $53,910 at an average of $11.98 per share.

The stock has experienced a total of 3 insider trades in the past three months. These trades include 3 buy trades. Furthermore, over the past 12 months , the stock was traded 8 times by insiders. In 3 of these trades, the insider was a seller while an employee of the company was the buyer in 5 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 3 0 8.27%
12 Month 5 3 -62.03%

Shares of Insys Therapeutics, Inc. (INSY) traded down 0.73% on Jun 13, 2017, hitting $10.87. 545,835 shares of the company’s stock traded hands. Insys Therapeutics, Inc. has a 52 week low of $9.07 and a 52 week high of $28.63. The company’s market cap is $916 million.

Insys Therapeutics, Inc. (INSY) last announced its earnings results on May 9, 2017. The company reported -0.09 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.10 by $0.01. The company had revenue of $36 million for the quarter, compared to the consensus estimate of $38 million. During the same quarter in the previous year, the company posted 0.11 earnings per share. The company’s revenue for the quarter was down 42% on a year-over-year basis.

2017-05-09 2017-04-03 2016-11-03 2016-08-03 2016-04-28 2016-02-23 2015-11-05 2015-08-06 2015-03-03 2014-11-11
earnings per share -0.09 0.03 0.07 0.13 0.11 0.36 0.50 0.21 0.53 0.63
Revenue(M) 35.96 54.86 55.18 67.12 61.96 91.14 91.26 77.63 66.51 58.3

Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, or BTCP, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting, or CINV, and appetite stimulation in AIDS patients. The Company’s proprietary Fentanyl SL Spray and its generic Dronabinol SG Capsule product candidates are both under review for marketing approval by the U.S. Food and Drug Administration, or FDA.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.